142 related articles for article (PubMed ID: 9814962)
1. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
Goldenthal KL; Vaillancourt JM; Geber A; Lucey DR
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S333-40. PubMed ID: 9814962
[TBL] [Abstract][Full Text] [Related]
2. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
3. Statistical evaluation of HIV vaccines in early clinical trials.
Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
5. Trial objectives and end points for measuring the efficacy of HIV vaccines.
Hoff R; Barker LF
Infect Agents Dis; 1995 Jun; 4(2):95-101. PubMed ID: 7613732
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
7. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
8. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L
J Infect Dis; 2003 Jul; 188(2):179-93. PubMed ID: 12854072
[TBL] [Abstract][Full Text] [Related]
9. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
WHO/UNAIDS/IAVI International Expert Group
AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582
[TBL] [Abstract][Full Text] [Related]
10. On the analysis of viral load endpoints in HIV vaccine trials.
Hudgens MG; Hoering A; Self SG
Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
[TBL] [Abstract][Full Text] [Related]
11. Update on HIV vaccines.
Meldorf M; Corey L
STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
[TBL] [Abstract][Full Text] [Related]
12. HIV vaccine development and evaluation: realistic expectations.
Heyward WL; MacQueen KM; Goldenthal KL
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S205-10. PubMed ID: 9814945
[TBL] [Abstract][Full Text] [Related]
13. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
[TBL] [Abstract][Full Text] [Related]
14. Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances.
Bansal GP; Malaspina A; Flores J
Curr Opin Mol Ther; 2010 Feb; 12(1):39-46. PubMed ID: 20140815
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible?
Excler JL; Beyrer C
J Hum Virol; 2000; 3(4):193-214. PubMed ID: 10990167
[TBL] [Abstract][Full Text] [Related]
16. Fifty volunteer for live-vaccine trial.
James JS
AIDS Treat News; 1997 Oct; (No 280):1-2. PubMed ID: 11364735
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 vaccine clinical trials: the Brazilian experience.
Ersching J; Pinto AR
Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
[TBL] [Abstract][Full Text] [Related]
18. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
[TBL] [Abstract][Full Text] [Related]
19. AIDS vaccine: efficacy, safety and ethics.
Veljkovic V; Veljkovic N; Glisic S; Ho MW
Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in AIDS vaccine research and development.
Johnston MI; Noe JS; Killen JY
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S317-23. PubMed ID: 7865330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
